Samjin Pharmaceutical Signs Joint Research Agreement with Canadian Cyclica for AI Drug Development

[Asia Economy Reporter Lee Gwan-joo] Samjin Pharmaceutical announced on the 2nd that it has signed a contract for joint AI drug development research with Cyclica, a Canadian artificial intelligence (AI) new drug development platform company.

Through this agreement, Samjin Pharmaceutical will propose multiple drug targets currently under review to Cyclica, and Cyclica will apply its AI-based new drug candidate discovery platforms (Ligand DesignTM, Ligand Express®) technology to rapidly secure highly developable candidate substances.

Lee Soo-min, head of the research center at Samjin Pharmaceutical, said, "Through joint research utilizing AI technology with Cyclica, we have been able to significantly reduce the time and cost required for new drug development, and this also allows for rapid scalability." He added, "Going forward, we plan to cooperate with leading domestic and international research institutions and companies to efficiently discover and develop innovative new drugs through an open innovation strategy."

Meanwhile, Cyclica was selected as one of the world's top 13 healthcare AI startups by CB Insights, a technology market research firm, in 2020. Currently, it is conducting joint research with numerous companies both domestically and internationally, including global big pharma such as Merck and AstraZeneca.

This content was produced with the assistance of AI translation services.